Reading view
Semantic Laundering in AI Agent Architectures: Why Tool Boundaries Do Not Confer Epistemic Warrant
WaterCopilot: An AI-Driven Virtual Assistant for Water Management
Why AI Alignment Failure Is Structural: Learned Human Interaction Structures and AGI as an Endogenous Evolutionary Shock
All Required, In Order: Phase-Level Evaluation for AI-Human Dialogue in Healthcare and Beyond
Imaging-anchored Multiomics in Cardiovascular Disease: Integrating Cardiac Imaging, Bulk, Single-cell, and Spatial Transcriptomics
GI-Bench: A Panoramic Benchmark Revealing the Knowledge-Experience Dissociation of Multimodal Large Language Models in Gastrointestinal Endoscopy Against Clinical Standards
Moral Lenses, Political Coordinates: Towards Ideological Positioning of Morally Conditioned LLMs
ISLA: A U-Net for MRI-based acute ischemic stroke lesion segmentation with deep supervision, attention, domain adaptation, and ensemble learning
DeKeyNLU: Enhancing Natural Language to SQL Generation through Task Decomposition and Keyword Extraction
Generative Digital Twins: Vision-Language Simulation Models for Executable Industrial Systems
Explainable Molecular Property Prediction: Aligning Chemical Concepts with Predictions via Language Models
Hallucination, reliability, and the role of generative AI in science
Efficient and Reproducible Biomedical Question Answering using Retrieval Augmented Generation
Aligning Trustworthy AI with Democracy: A Dual Taxonomy of Opportunities and Risks
Foundations of LLM Knowledge Materialization: Termination, Reproducibility, Robustness
STAT+: On Day 2 of JPM, Gilead lays outs it next test, a VC looks to raise funds, and one firm has FDA whiplash
This is the online version of The Readout, STAT’s flagship biotech newsletter. Sign up to get it in your inbox.
You’re back. We’re sort of back. It’s Day 2 of JPM and we’re definitely not exhausted or delirious yet.
This is Elaine Chen, Adam Feuerstein, Matt Herper, and Allison DeAngelis again. We’ve got a lot more news today, so let’s get to it.
The next test for Kite Pharma — and Gilead
It’s anito-cel, the CAR-T therapy for multiple myeloma that Gilead is developing in partnership with Arcellx. Gilead submitted the therapy to the FDA sometime before the end of December, Cindy Perettie, executive vice president of Kite Pharma, the cell therapy division of Gilead, told STAT at a Gilead media breakfast.
Continue to STAT+ to read the full story…


© Alex Hogan/STAT
Microsoft announces glut of new data centers but says it won’t let your electricity bill go up
Assessment of the Diagnostic Performance and Clinical Impact of AI in Hepatic Steatosis: Systematic Review and Meta-Analysis
Google Introduces Conductor, a Context-Driven Development Extension for Gemini CLI

Google has released Conductor, a new preview extension for Gemini CLI that introduces a structured, context-driven approach to AI-assisted software development. The extension is designed to address a common limitation of chat-based coding tools: the loss of project context across sessions.
By Robert Krzaczyński